Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2022 Feb 21;28(12):2579–2586. doi: 10.1158/1078-0432.CCR-21-3951

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

©2022 The Authors; Published by the American Association for Cancer Research

This open access article is distributed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0) license.

PMC Copyright notice

Figure 3. Somatic gain of MYC and loss of PTEN is associated with worse OS and PFS respectively in patients with detectable circulating tumor DNA. A, OS in patients with copy-gain of MYC and (B) PFS in patients with copy-loss of PTEN in patients with detectable ctDNA prior to therapy. — Somatic gain of MYC and loss of PTEN are associated with worse OS and PFS, respectively, in patients with detectable circulating tumor DNA. A, OS in patients with copy-gain of MYC and (B) PFS in patients with copy-loss of PTEN among patients with detectable ctDNA prior to therapy.